Palliative chemotherapy for malignant pheochromocytoma: Symptomatic palliation of two cases

Internal Medicine

Volumn 38, Issue 5, 1999, Pages 433-435

  Iwabuchi, Masayasu ^a   Oki, Yutaka ^a   Nakamura, Hirotoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metastasis; Cytosine arabinoside; Individualized modification; Pulmonary edema; Quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CASE REPORT; CATECHOLAMINE BLOOD LEVEL; FEMALE; HUMAN; LUNG EDEMA; MALE; PHEOCHROMOCYTOMA;

EID: 0033017238     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.433     Document Type: Article

References (13)

1. Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 7: 118-124, 1985.
2. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109: 267-273, 1988.
3. WHO handbook for reporting results of cancer treatment. Geneva. World Health Organization, 1979.
4. Senan S, Reed N, Connell J. Palliation of malignant phaechromocytoma with combination chemotherapy. Eur J Cancer 28A: 1007-1008, 1992.
5. Sjoerdsma A, Engelman K, Waldmann TA, et al. Pheochromocytoma: current concepts of diagnosis and treatment. Combined clinical staff conference at the National Institute of Health. Ann Intern Med 65: 1302-1326, 1966.
6. Matsushita A, Takesue H, Ikeda M. et al. General pharmacology of vindesine sulfate. (3) Changes in motor behaviors and muscle spindle activities of the cat following chronic administration of vindesine and vincristine. Ouyou Yakuri 25: 655-662, 1983 (in Japanese).
7. Hill BT, Whelan RD. Assessment of the sensitivities of cultured human neuroblastoma cells to anti-tumor drugs. Pediatr Res 15: 1117-1122, 1981.
8. Shackney SE, Bunn PA, Ford SS, Erickson B, Ross WE, Levine AS. A study of drug-induced kinetic perturbations in the marrow of a patient with neuroblastoma. Cancer 45: 882-892, 1980.
9. Starling KA, Sutow WW, Donaldson MH, Land VJ, Lane DM. Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) alone; vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaplopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone. Cancer Chemother Rep 58: 683-688, 1974.
10. Siddiqui MZ, Von Eyben FE, Spanos G. High-voltage irradiation and combination chemotherapy for malignant pheochromocytoma. Cancer 62: 686-690, 1988.
11. Baccarani M, Tura S. Differentiation of myeloid leukaemic cells: new possibilities for therapy. Br J Haematol 42: 485-487, 1979.
12. Housset M, Daniel MT. Degos L. Small doses of ARA-C in the treatment of acute myeloid leukemia: differentiation of myeloid leukaemia cells? Br J Haematol 51: 125-129, 1982.
13. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15: 631-642, 1992.